Dec 14 (Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab had been fulfilled ...

Nov. 7, 2024 — Scientists are developing a formula for success -- by studying how a new type of battery fails. The team's goal is the design for long-term storage of wind and solar energy ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

After hours: 7:13:59 p.m. EST Loading Chart for NVO ...

Spot lithium carbonate prices to have a slight downward space due to potential demand reduction China’s critical minerals ban: A new front in USA-China trade conflict POSCO Pilbara JV will supply ...